Rallybio Corp

RLYB

Company Profile

  • Business description

    Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

  • Contact

    234 Church Street
    Suite 1020
    New HavenCT06510
    USA

    T: +1 203 859-3820

    https://www.rallybio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    24

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,770.6025.40-0.29%
CAC 407,684.6880.43-1.04%
DAX 4023,516.23255.22-1.07%
Dow JONES (US)42,586.59381.03-0.89%
FTSE 1008,850.6334.29-0.39%
HKSE23,892.56142.82-0.59%
NASDAQ19,585.6076.88-0.39%
Nikkei 22537,834.25338.84-0.89%
NZX 50 Index12,552.8796.23-0.76%
S&P 5006,025.2620.00-0.33%
S&P/ASX 2008,547.4017.70-0.21%
SSE Composite Index3,377.0025.66-0.75%

Market Movers